AzTrials
AzTrials

AngioplastyNCT06127134

Outcomes of Straight-line Flow Versus Angiosome-targeted Angioplasty in Treatment of Critical Lower Limb Ischemia

A study testing peripheral angioplasty for tibial vessels in people with Angioplasty and Critical Lower Limb Ischemia, run by Kafrelsheikh University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations. The ischemic limb must be revascularized to help wound healing, reduce the pain of ischemia and preserve the limb's function. Read more about this study

Who is it for?
Any age
Conditions the study is for
Angioplasty, Critical Lower Limb Ischemia
What is being tested?
peripheral angioplasty for tibial vessels
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
100 participants
Where
1 siteEgypt
Study dates
1 Jan 2023to 1 Jan 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Patient with documented symptomatic infragenicular chronic arterial disease with or without supra-genicular lesion
  • Diabetic or not
  • Rutherford grades 4, 5 and 6
  • The patient is able and willing to comply with study follow-up requirements.

Who cannot join

  • Contraindication for angioplasty
  • unsuitable for angioplasty revascularization strategy
  • claudication case
  • tissue loss is considered to be primarily of venous etiology.
  • Patient with full-thickness gangrene of the foot.
  • Widespread infection of the lower limb needing amputation

Trial locations and contacts

1 site in 1 country.

Egypt1 site
  • Kafrelsheikh University

    Kafr ash Shaykh

Other trials in Egypt

About this study

Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations.

The ischemic limb must be revascularized to help wound healing, reduce the pain of ischemia and preserve the limb's function. So, surgical and percutaneous revascularization choices must be considered in CLI. Classically, CLI revascularization aims to provide at least one patent vessel that delivers in-line flow to the foot.

Read more

Today, the investigators live in a new era of angioplasty evolving and substituting open vascular surgery, so expanding research on endovascular strategy has been noticed.This confirms the profound impact of angioplasty in vascular surgery as one of the fastest-growing branches of medicine

Infrapopliteal artery occlusive disease (IPOD) is a significant cause of critical limb-threatening ischemia (CLTI). The worldwide prevalence of IPOD is between 4.5% and 29%, and most patients live in low-income countries.

The angiosomal concept was derived from plastic surgery for the skin flap. This concept delineates the human body into three-dimensional blocks of tissue from the skin to bone and also provides practical application of vascular anatomy for reconstructive surgery. An angiosome is an anatomic unit of tissue consisting of skin, subcutaneous, muscle, and bone fed by a source artery and drained by a specific vein.

According to the angiosomal concept, the foot is divided into six distinct angiosomes fed by source arteries, three from the posterior tibial, two from the peroneal, and one from the anterior tibial artery, with functional artery-to-artery connections among muscle, fascia, and skin. Numerous direct inter-arterial connections occur between the foot's main arteries, which provide alternative pathways of blood flow when disruption or compromise affects the arteries that directly feed the angiosome.

On the other hand, in patients with CLI, where only one vessel runoff can be established to the foot, direct flow into a patent pedal arch is essential to improve their clinical outcomes.

Conventional Endovascular therapy aims to the re-establishment of pulsatile straight-line flow to the lower limb. This results in relieving ischemic pain, healing ulcers, achieving limb salvage, improving quality of life, and potentially prolonging survival.

So it became essential to know the differential impact of both concepts on CLI revascularization.

Read the detailed description

Introduction

Peripheral arterial disease (PAD) affects more than 200 million people worldwide. Although over 50% are asymptomatic, it accounts for 4% of all amputations.

The ischemic limb must be revascularized to help wound healing, reduce the pain of ischemia and preserve the limb's function. So, surgical and percutaneous revascularization choices must be considered in CLI. Classically, CLI revascularization aims to provide at least one patent vessel that delivers in-line flow to the foot.

Today, the investigators live in a new era of angioplasty evolving and substituting open vascular surgery, so expanding research on endovascular strategy has been noticed.This confirms the profound impact of angioplasty in vascular surgery as one of the fastest-growing branches of medicine

Infrapopliteal artery occlusive disease (IPOD) is a significant cause of critical limb-threatening ischemia (CLTI). The worldwide prevalence of IPOD is between 4.5% and 29%, and most patients live in low-income countries.

The angiosomal concept was derived from plastic surgery for the skin flap. This concept delineates the human body into three-dimensional blocks of tissue from the skin to bone and also provides practical application of vascular anatomy for reconstructive surgery. An angiosome is an anatomic unit of tissue consisting of skin, subcutaneous, muscle, and bone fed by a source artery and drained by a specific vein.

According to the angiosomal concept, the foot is divided into six distinct angiosomes fed by source arteries, three from the posterior tibial, two from the peroneal, and one from the anterior tibial artery, with functional artery-to-artery connections among muscle, fascia, and skin. Numerous direct inter-arterial connections occur between the foot's main arteries, which provide alternative pathways of blood flow when disruption or compromise affects the arteries that directly feed the angiosome.

On the other hand, in patients with CLI, where only one vessel runoff can be established to the foot, direct flow into a patent pedal arch is essential to improve their clinical outcomes.

Conventional Endovascular therapy aims to the re-establishment of pulsatile straight-line flow to the lower limb. This results in relieving ischemic pain, healing ulcers, achieving limb salvage, improving quality of life, and potentially prolonging survival.

So it became essential to know the differential impact of both concepts on CLI revascularization.

Aim of the work Comparing the efficiency of two percutaneous transluminal angioplasty techniques for Critical Lower Limb Ischemia revascularization, Straight-line flow (Group A) versus Angiosome-targeted (Group B).As regard short-term impact.

Patient and methods

  1. Study Ethics the investigators will conduct this study after the approval of the I.R.B. (Institutional Review Board) of Kafrelsheikh University Hospital. All included procedures will be according to the Declaration of Helsinki. the investigators will also obtain the patients' informed consent to use their data in their research. All evaluation forms, reports, and other records that leave the site would not include unique personal data to maintain subject confidentiality.
  2. Study design: a non-randomized clinical trial.
  3. Time of study: The study will be conducted in 2023.
  4. all patients will be submitted to the following preoperative evaluation : 1-History : 1. Personal data. 2. Risk factors: smoking, DM, hypertension, hypercholesterolemia. 3. Co-morbidity: previous stroke, angina, MI, and CKD. 4. Previous PAD interventions to one or both legs. 5. Previous amputations. 6. Previous coronary intervention (CABG, PCI) 2- Physical examination, including:
  5. Assessment of functional status: independent stick walker, prosthesis, wheelchair, bed-bound 2. Recording of peripheral pulses 3. Measurement of ABPI or TBPI 4. Wound assessment (in those patients with tissue loss) 5. Assessment of ischaemic night/rest pain. 3-Investigations: A) Laboratory
  6. Routine hematology (hemoglobin, white cell count, platelet count, HbA1c)
  7. Routine biochemistry (creatinine, estimated GFR, ESR, CRP, RBS, cholesterol, HBA1c)
  8. PT, PTT, INR
  9. Lipid profile.

B)Imaging of their arteries by one or more of the following modalities:

  1. Duplex ultrasound.
  2. Computerized tomography angiography (CTA)
  3. Magnetic resonance angiography (MRA)
  4. Digital subtraction angiography (DUS) (5) Patients with critical lower limb ischemia are going to be classified according to
  • Modified TASC II classification 2016 (Trans-Atlantic Inter-society Consensus), which is a morphological classification
  • Rutherford classification, which is the clinical classification (6) Surgical procedure. Therapeutic intervention (angioplasty) (7) Post-operative follow-up.

Follow-up of the patients will be at the first, third, and sixth months from the intervention date. Progress of limb conditions after the intervention will be observed which will be regarding :

  • Diminution or absence of rest pain
  • Healing of ulcers.
  • limb salvage Assessed by Visual Analogue Scale (VAS)
  • complications (8) Sampling technique:

The sample size of 100 patients classified into two groups

(9) Statistical analysis:

Analysis of data will be done using SPSS (statistical package for social science)

(10) Inclusion Criteria:

  • Patient with documented symptomatic infragenicular chronic arterial disease with or without supra-genicular lesion
  • Diabetic or not
  • Rutherford grades 4, 5 and 6
  • The patient is able and willing to comply with study follow-up requirements. (11) Exclusion Criteria:
  • Contraindication for angioplasty
  • unsuitable for angioplasty revascularization strategy
  • claudication case
  • tissue loss is considered to be primarily of venous etiology.
  • Patient with full-thickness gangrene of the foot.
  • Widespread infection of the lower limb needing amputation (12) Outcome Measures :
  • Technical success as documented by angiography pre \& post procedure with residual stenosis <30%
  • Clinical success is improving at least one class in Rutherford classification in patients with chronic limb ischemia.
  • Primary patency at six months follow-up.
  • Successful target lesion revascularization.
  • The absence of major adverse events is defined as unplanned major amputation of the index limb.
  • Absence of non-managed complications
Being tested
peripheral angioplasty for tibial vessels
Keywords
angioplasty, critical lower limb ischemia, chronic lower limb threatening ischemia, straight line, angiosome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • peripheral angioplasty for tibial vesselsProcedure or surgery

    Also called endovascular arterial repair for critical lower limb ischemia

    repair tibials blood vessels throughout two concepts using angioplasty ballooning

Study groups in NCT06127134
Study groupRoleWhat they receive
Straight-line flow (Group A)Active comparatortreating less diseased arteries which is in line with distal run off the foot
Receives: Procedure: peripheral angioplasty for tibial vessels
Angiosome-targeted (Group B)Sham comparatortreating specific angiosome through a targeted vessel which mainly supplies this angiosome
Receives: Procedure: peripheral angioplasty for tibial vessels

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Technical success

    good distal flow and arterial pulsation which are documented by angiography pre \& post procedure with residual stenosis <30%

    Measured: first 24 hours

  2. Clinical success

    limb salvage and wound status improves at least one class in Rutherford classification in patients with critical limb ischemia.

    Measured: first 6 month

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Nov 2023
  2. Study start1 Jan 2023
  3. Primary completion15 Nov 2023 (estimated)
  4. Study completion1 Jan 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06127134
Sponsor's protocol ID
MSKU 50-2-28
Status last verified
Nov 2023
First submitted
7 Nov 2023
Last updated
14 Nov 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing peripheral angioplasty for tibial vessels in people with Angioplasty and Critical Lower Limb Ischemia, run by Kafrelsheikh University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 14 Nov 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Technical success (time frame: first 24 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Nov 2023; AzTrials last refreshed its copy on 8 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in